New Risk • May 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€7.1m net loss in 2 years). Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (€2.3m revenue, or US$2.7m). Market cap is less than US$100m (€64.5m market cap, or US$75.7m). Annuncio • Apr 26
Afyren Receives EUR 3 Million Grant from Grand Est Region Through European Just Transition Fund Afyren received a EUR 3 million grant from the Grand Est Region through the European Just Transition Fund. The European Union has established the Just Transition Fund in the most strategic regions and sectors. In order to meet the actual needs of local territories, Europe has entrusted management of these funds to selected regions. In this context, Afyren was selected by the Grand Est Region to benefit from this support, which will contribute to financing performance investments at the Afyren Neoxy plant, now 100% owned by Afyren. This grant illustrates the development potential of the biorefinery and, more broadly, the creation of value, jobs, and sustainable skills driven by the company, one of the few greentech players to have successfully crossed the threshold of industrial-scale production and commercialization. It is also in recognition of this level of maturity, and thanks to the achievement of the defined milestones, that Afyren received the final instalment of EUR 2.2 million in March 2026 under Bpifrance’s “France Relance” grant, aimed at supporting strategic investments in critical sectors. Annuncio • Apr 02
AFYREN SAS, Annual General Meeting, Jun 16, 2026 AFYREN SAS, Annual General Meeting, Jun 16, 2026. Location: lyon France Reported Earnings • Apr 02
Full year 2025 earnings released Full year 2025 results: Net income: (up €9.75m from FY 2024). New Risk • Apr 02
New major risk - Revenue and earnings growth Earnings have declined by 28% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 28% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€7.1m net loss in 2 years). Revenue is less than US$5m (€2.7m revenue, or US$3.1m). Market cap is less than US$100m (€68.0m market cap, or US$78.3m). Annuncio • Apr 01
AFYREN SAS (ENXTPA:ALAFY) acquired remaining 49% stake in Afyren Neoxy from Fonds Sociétés de Projets Industriels, FPCI funds managed by Bpifrance Investissement SAS for €11.3 million. AFYREN SAS (ENXTPA:ALAFY) acquired remaining 49% stake in Afyren Neoxy from Fonds Sociétés de Projets Industriels, FPCI funds managed by Bpifrance Investissement SAS for €11.3 million on March 31, 2026. As a result of the transaction, AFYREN now holds 100% of the subsidiary
AFYREN SAS (ENXTPA:ALAFY) completed the acquisition of remaining 49% stake in Afyren Neoxy from Fonds Sociétés de Projets Industriels, FPCI funds managed by Bpifrance Investissement SAS on March 31, 2026. New Risk • Mar 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€10.0m net loss in 2 years). Revenue is less than US$5m (€2.7m revenue, or US$3.1m). Market cap is less than US$100m (€71.5m market cap, or US$82.4m). Annuncio • Feb 27
AFYREN SAS has completed a Follow-on Equity Offering in the amount of €7 million. AFYREN SAS has completed a Follow-on Equity Offering in the amount of €7 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,745,098
Price\Range: €2.55 Annuncio • Jan 15
AFYREN Provides Revenue Guidance for the Full Year 2026 AFYREN provides revenue guidance for the full year 2026. For the period, The company expects revenue growth to accelerate. Major Estimate Revision • Nov 27
Consensus EPS estimates upgraded to €0.35 loss The consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -€0.495 to -€0.355 per share. Revenue forecast unchanged from €3.20m at last update. Chemicals industry in France expected to see average net income growth of 18% next year. Consensus price target down from €5.20 to €5.00. Share price rose 8.1% to €2.41 over the past week. Annuncio • Nov 26
AFYREN SAS announced that it has received €22.999999 million in funding from Kemin Industries, Bpifrance Investissement SAS AFYREN SAS announced a private placement of 95,83,333 common shares at a price of €2.40 per share for gross proceeds of €22,999,999.20 on November 25, 2025. The transaction included participation from new investor Kemin Industries, and returning investor Bpifrance Investissement SAS. Reported Earnings • Sep 12
First half 2025 earnings released: €0.27 loss per share (vs €0.20 loss in 1H 2024) First half 2025 results: €0.27 loss per share (further deteriorated from €0.20 loss in 1H 2024). Net loss: €6.92m (loss widened 30% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. Annuncio • Sep 12
Afyren Sas Provides Revenue Guidance for 2025 AFYREN SAS provided revenue guidance for 2025. For the period, the company expects production revenue in the low single-digit million euros range. Major Estimate Revision • Jul 18
Consensus revenue estimates increase by 867%, EPS downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €3.00m to €29.0m. EPS estimate fell from -€0.33 to -€0.61 per share. Chemicals industry in France expected to see average net income growth of 12% next year. Consensus price target of €5.00 unchanged from last update. Share price fell 2.2% to €2.26 over the past week. New Risk • Jul 18
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€8.5m net loss in 3 years). Revenue is less than US$5m (€2.9m revenue, or US$3.3m). Market cap is less than US$100m (€59.5m market cap, or US$69.3m). New Risk • Jul 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.8m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€8.3m net loss in 3 years). Revenue is less than US$5m (€2.9m revenue, or US$3.4m). Market cap is less than US$100m (€70.5m market cap, or US$83.3m). Major Estimate Revision • Jun 18
Consensus revenue estimates decrease by 32% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from €4.40m to €3.00m. EPS estimate unchanged from -€0.33 per share at last update. Chemicals industry in France expected to see average net income growth of 13% next year. Consensus price target of €5.00 unchanged from last update. Share price rose 6.8% to €2.99 over the past week. Annuncio • Apr 10
AFYREN SAS Appoints Laurent Pou as Industrial Director AFYREN SAS announces the strengthening of its Executive Committee with the appointment of Laurent Pou as Industrial Director, a strategic position as the Group’s first biorefinery, AFYREN NEOXY, enters the final phase of industrial start-up. A chemical engineering graduate of ENSIC Nancy and University College London, Laurent Pou has extensive experience with international companies such as Tereos and ExxonMobil. His 25 years’ experience in the chemicals and agrochemicals industry and his strong expertise in industrial plant start-ups, operations management and the industrial and economic optimisation of production assets are key strengths for the forthcoming continuous operation phase of AFYREN NEOXY and the ramp-up period that will follow. This appointment follows on from the strengthening of the Executive Committee around industrial skills: Ursula Feulner, Director of Industrial Projects since early 2022, joined AFYREN’s Executive Committee in 2024. Reported Earnings • Mar 27
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: €0.37 loss per share (in line with FY 2023). Net loss: €9.75m (loss widened 1.8% from FY 2023). Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates by 35%. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings. Price Target Changed • Mar 25
Price target increased by 10% to €5.00 Up from €4.53, the current price target is an average from 2 analysts. New target price is 212% above last closing price of €1.61. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.57 next year compared to a net loss per share of €0.37 last year. New Risk • Feb 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€7.8m net loss in 3 years). Revenue is less than US$5m (€2.8m revenue, or US$2.9m). Market cap is less than US$100m (€57.4m market cap, or US$60.3m). Annuncio • Jan 17
AFYREN SAS, Annual General Meeting, Jun 17, 2025 AFYREN SAS, Annual General Meeting, Jun 17, 2025. Reported Earnings • Oct 04
First half 2024 earnings released: €0.20 loss per share (vs €0.20 loss in 1H 2023) First half 2024 results: €0.20 loss per share (further deteriorated from €0.20 loss in 1H 2023). Net loss: €5.32m (loss widened 3.9% from 1H 2023). Revenue is forecast to grow 99% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 28% per year whereas the company’s share price has fallen by 29% per year. Annuncio • Oct 01
AFYREN Provides Production Guidance for the Year 2024 AFYREN provided production guidance for the year 2024. The company aims for: three production units with an installed capacity of around 70,000 tons of acids in 2028, including at least two in continuous production (including the existing AFYREN NEOXY plant). These three units will also produce a high added-value fertilizer to ensure the circularity of the model; With all three units running at full capacity, the company aims for: cumulated production revenue of more than €150 million. Annuncio • Jul 09
AFYREN's Fermentation Lab Reaches 2-Million-Hour Mark as It Identifies New Raw Materials to Fuel Industrial Expansion AFYREN announced that it confirms its innovative approach and identifies the biomass families that will underpin its industrial expansion. The announcement comes as the company hit the milestone of 2 million hours of fermentation in its R&D lab. A unique technology based on biomimicry: Based on a decade of research in chemistry and biology and protected worldwide by 10 patent families, the AFYNERIE® process converts a wide range of organic raw materials into bio-based molecules using natural, non-genetically modified micro-organisms. Inspired by living organisms and entirely biomimetic, the process reproduces on an industrial scale the fermentation that has been around for millions of years in natural ecosystems and on which, for example, the mechanization process, used for energy production, is based. AFYREN's expertise lies in controlling the transformation of the bio-based raw material to promote the production of carboxylic acids. The acids are extracted then processed through separation and purification stages to obtain products that meet industry specifications and current regulations. This quality is at the heart of the 'drop-in' approach, which enables direct replacement of petro-based molecules by bio-based molecules in its clients' existing production process. The end products are commonly found for example in food products or cosmetics, opening up markets that go well beyond those offered by mechanization. 60 biomass families identified and available to support AFYREN's international development and secure its supply of raw materials. On the strength of its successful experience in valorizing by-products from the sugar industry at the AFYREN NEOXY plant in France, AFYREN is continuing its work to identify new sources of raw materials. Since the company was founded, AFYREN's R&D teams, made up of chemists and biologists, have carried out tests on more than 300 potential raw materials made available by the players and partners in the agri-food and farming industries around the world. These tests have enabled AFYREN to qualify 60 families of biomass (agricultural by-products, by-products of the food industry, etc.) that can be transformed into 100% bio-based molecules on an industrial scale. The recent partnership signed with SUEZ even paves the way for the recovery of household organic waste. This work proves that a wide range of organic raw materials can be upcycled in this way, even though they were originally considered to be of little use. This work, carried out on samples from all over the world, is crucial for international development at AFYREN, whose strategy is based on short supply chains with regional sourcing. Innovation fully dedicated to the development of new circular value chains: AFYREN's innovation approach is based on three strategic pillars. Each project must aim to improve processes, support international expansion by exploring new biomass families, or contribute to the development of innovative products and derivatives. For this work, partnerships are often the preferred option. Within this framework, R&D is working in particular on perfecting processes to optimize yields and make AFYREN's industrial solution more competitive. Working closely with the business development team, the R&D teams are also trying to expand the company’s portfolio of acids and their derivatives. The acids produced by AFYREN are platform molecules which, thanks to additional green chemistry steps (esterification, hydrogenation, etc.) can be transformed into derivatives and new products. AFYREN's innovation portfolio currently comprises around ten projects aimed at developing partnerships for new products and circular value chains. It follows an eco-design rationale, incorporating corporate social responsibility (CSR) performance criteria such as carbon footprint, energy mix or the nature of raw materials and their transport. New Risk • May 08
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 9.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings are forecast to decline by an average of 9.9% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€11m net loss in 3 years). Revenue is less than US$5m (€3.4m revenue, or US$3.6m). Market cap is less than US$100m (€70.5m market cap, or US$75.9m). Major Estimate Revision • Apr 09
Consensus revenue estimates decrease by 14%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €4.07m to €3.50m. EPS estimate increased from -€0.723 to -€0.44 per share. Chemicals industry in France expected to see average net income growth of 20% next year. Consensus price target down from €6.30 to €5.75. Share price rose 2.9% to €1.96 over the past week. Reported Earnings • Apr 03
Full year 2023 earnings released: €0.37 loss per share (vs €0.36 loss in FY 2022) Full year 2023 results: €0.37 loss per share (further deteriorated from €0.36 loss in FY 2022). Net loss: €9.59m (loss widened 4.2% from FY 2022). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in France. New Risk • Jan 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 41% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€5.6m net loss in 3 years). Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (41% increase in shares outstanding). Revenue is less than US$5m (€3.6m revenue, or US$4.0m). Market cap is less than US$100m (€73.4m market cap, or US$79.8m). New Risk • Dec 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€4.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.7m free cash flow). Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Revenue is less than US$5m (€3.6m revenue, or US$4.0m). Market cap is less than US$100m (€53.3m market cap, or US$58.1m). Price Target Changed • Dec 15
Price target decreased by 18% to €7.17 Down from €8.77, the current price target is an average from 3 analysts. New target price is 248% above last closing price of €2.06. Stock is down 67% over the past year. The company is forecast to post a net loss per share of €0.43 next year compared to a net loss per share of €0.36 last year. New Risk • Oct 28
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €94.2m (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Revenue is less than US$5m (€3.6m revenue, or US$3.9m). Market cap is less than US$100m (€94.2m market cap, or US$99.5m). Major Estimate Revision • Sep 26
Consensus revenue estimates increase by 14% The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from €3.43m to €3.90m. Forecast losses expected to reduce from -€0.53 to -€0.435 per share. Chemicals industry in France expected to see average net income growth of 1.4% next year. Consensus price target broadly unchanged at €8.60. Share price fell 5.2% to €4.74 over the past week. Reported Earnings • Sep 20
First half 2023 earnings released: €0.20 loss per share (vs €0.16 loss in 1H 2022) First half 2023 results: €0.20 loss per share (further deteriorated from €0.16 loss in 1H 2022). Net loss: €5.12m (loss widened 23% from 1H 2022). Revenue is forecast to grow 87% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in France. Price Target Changed • Sep 20
Price target decreased by 7.5% to €8.60 Down from €9.30, the current price target is an average from 3 analysts. New target price is 74% above last closing price of €4.93. Stock is down 30% over the past year. The company is forecast to post a net loss per share of €0.43 next year compared to a net loss per share of €0.36 last year. New Risk • Jul 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€3.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.8m free cash flow). Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€16m net loss in 3 years). Share price has been volatile over the past 3 months (6.6% average weekly change). Revenue is less than US$5m (€3.5m revenue, or US$3.8m). Major Estimate Revision • Mar 29
Consensus EPS estimates fall by 15% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€0.363 to -€0.417 per share. Revenue forecast of €3.80m unchanged since last update. Chemicals industry in France expected to see average net income decline 0.5% next year. Consensus price target down from €9.30 to €8.77. Share price fell 3.7% to €4.71 over the past week. Reported Earnings • Mar 22
Third quarter 2022 earnings released: €0.099 loss per share (vs €0.048 loss in 3Q 2021) Third quarter 2022 results: €0.099 loss per share (further deteriorated from €0.048 loss in 3Q 2021). Net loss: €2.52m (loss widened 144% from 3Q 2021). Revenue is forecast to grow 57% p.a. on average during the next 4 years, compared to a 4.0% growth forecast for the Chemicals industry in France. Annuncio • Jan 10
AFYREN Announces Appointment to Its Management Team AFYREN announced the appointment of three new members to its management team as well as new hires to support its development in France and abroad and to step up its R&D activities. Three strategic appointments Ursula Feulner - Director for Industrial Project Management:- Ursula joins AFYREN's operations team and will lead the upstream phases of industrial projects, including the construction of new plants. AFYREN benefits from her long experience with the SUEZ Group, where she had various roles closely related to the management of industrial projects in Europe, North America, the Middle East and Asia, and worked in risk management for a number of strategic projects. Lea Bassegoda - Human Resources Director:- Lea joins AFYREN to supervise the expansion of its teams. After several years in France and the United States with LVMH and then Danone, she will use her skills and solid experience to build a global Human Resources policy within the group and to structure the organization in line with the company's culture and strong values. Christophe Dardel - Strategic Partnerships Director:- Christophe has come onboard to identify and lay the groundwork for future international factory projects and related strategic partnerships. He has long and solid international experience acquired at several companies, and in particular with Royal DSM for more than 15 years. As a former member of the Executive Committee, Christophe was in charge of the development of the DSM Dyneema unit, which experienced strong organic growth through the establishment of several factories and key partnerships around the world. Price Target Changed • Nov 16
Price target decreased to €9.30 Down from €10.70, the current price target is an average from 3 analysts. New target price is 89% above last closing price of €4.93. Stock is down 46% over the past year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Patrizia Marraghini was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 28
First half 2022 earnings released: EPS: €0 (vs €0.44 loss in 1H 2021) First half 2022 results: EPS: €0. Net loss: €4.16m (loss widened 170% from 1H 2021). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Chemicals industry in France. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Chairman of the Board Stefan Borgas was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 30
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Chairman of the Board Stefan Borgas was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
